Search results for "Hyperthyroidism"

showing 10 items of 32 documents

Double-Blind, Placebo-Controlled, Randomized Trial of Selenium in Graves Hyperthyroidism.

2017

Abstract Context Supplemental selenium (Se) may affect the clinical course of Graves disease (GD). Objective Evaluate efficacy of add-on Se on medical treatment in GD. Design Double-blind, placebo-controlled, randomized supplementation trial. Setting Academic endocrine outpatient clinic. Patients Seventy untreated hyperthyroid patients with GD. Intervention Additionally to methimazole (MMI), patients received for 24 weeks either sodium selenite 300 µg/d po or placebo. MMI was discontinued at 24 weeks in euthyroid patients. Main Outcome Measures Response rate (week 24), recurrence rate (week 36), and safety. Results A response was registered in 25 of 31 patients (80%) and in 27 of 33 (82%) a…

0301 basic medicineAdultMalemedicine.medical_specialtySide effectEndocrinology Diabetes and MetabolismGraves' diseaseClinical Biochemistry030209 endocrinology & metabolismContext (language use)PlaceboBiochemistryHyperthyroidismlaw.inventionPlacebos03 medical and health sciencesSelenium0302 clinical medicineEndocrinologyRandomized controlled trialDouble-Blind MethodlawRecurrenceInternal medicineMedicineOutpatient clinicHumansEuthyroidAdverse effectbusiness.industryBiochemistry (medical)Middle Agedmedicine.diseaseGraves Disease030104 developmental biologyEndocrinologyTreatment OutcomeDietary SupplementsFemalebusinessThe Journal of clinical endocrinology and metabolism
researchProduct

Integrative analysis of key candidate genes and signaling pathways in autoimmune thyroid dysfunction related to anti-CTLA-4 therapy by bioinformatics

2020

Summary Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), the first immune checkpoint to be targeted clinically, has provided an effective treatment option for various malignancies. However, the clinical advantages associated with CTLA-4 inhibitors can be offset by the potentially severe immune-related adverse events (IRAEs), including autoimmune thyroid dysfunction. To investigate the candidate genes and signaling pathways involving in autoimmune thyroid dysfunction related to anti-CTLA-4 therapy, integrated differentially expressed genes (DEGs) were extracted from the intersection of genes from Gene Expression Omnibus (GEO) datasets and text mining. The functional enrichment was perfo…

0301 basic medicineCandidate geneCD74Signaling pathway.FCGR2BDifferentially expressed geneBiologyBioinformaticsHyperthyroidismAutoimmune Diseases03 medical and health sciencesMice0302 clinical medicineHypothyroidismmedicineAnimalsHumansPharmacology (medical)CTLA-4 AntigenProtein Interaction MapsKEGGGeneImmune Checkpoint InhibitorsPharmacologyPreclinical StudiesSignaling pathwayCancerComputational Biologymedicine.diseaseImmune checkpointGene Expression Regulation Neoplastic030104 developmental biologyGene OntologyAutoimmune thyroid dysfunctionOncologyCTLA-4030220 oncology & carcinogenesisDifferentially expressed genesCTLA-4BiomarkersImmune checkpoint blockadeSignal Transduction
researchProduct

Thyroid Dysfunction and Diabetes Mellitus: Two Closely Associated Disorders

2019

Thyroid dysfunction and diabetes mellitus are closely linked. Several studies have documented the increased prevalence of thyroid disorders in patients with diabetes mellitus and vice versa. This review critically discusses the different underlying mechanisms linking type 1 and 2 diabetes and thyroid dysfunction to demonstrate that the association of these two common disorders is unlikely a simple coincidence. We assess the current state of knowledge on the central and peripheral control of thyroid hormone on food intake and glucose and lipid metabolism in target tissues (such as liver, white and brown adipose tissue, pancreatic b cells, and skeletal muscle) to explain the mechanism linking…

0301 basic medicineendocrine system diseasesEndocrinology Diabetes and MetabolismReviews030209 endocrinology & metabolismType 2 diabetesBioinformatics03 medical and health sciences0302 clinical medicineEndocrinologyHypothyroidismDiabetes mellitusmedicineAnimalsHumansSubclinical infectionType 1 diabetesbusiness.industryThyroidmedicine.diseaseThyroid DiseasesDiabetes Mellitus Type 1030104 developmental biologymedicine.anatomical_structureDiabetes Mellitus Type 2Metabolic control analysisMetabolic syndromeHyperthyroidism Hypothyroidism type 1 diabetes mellitus type 2 diabetes mellitus metabolic syndrome pregnancy guidelinesbusinessHormoneEndocrine Reviews
researchProduct

Insulin resistance and diabetes in hyperthyroidism: a possible role for oxygen and nitrogen reactive species.

2019

In addition to insulin, glycemic control involves thyroid hormones. However, an excess of thyroid hormone can disturb the blood glucose equilibrium, leading to alterations of carbohydrate metabolism and, eventually, diabetes. Indeed, experimental and clinical hyperthyroidism is often accompanied by abnormal glucose tolerance. A common characteristic of hyperthyroidism and type 2 diabetes is the altered mitochondrial efficiency caused by the enhanced production of reactive oxygen and nitrogen species. It is known that an excess of thyroid hormone leads to increased oxidant production and mitochondrial oxidative damage. It can be hypothesised that these species represent the link between hype…

0301 basic medicinemedicine.medical_specialtyendocrine systemendocrine system diseasesmedicine.medical_treatmentDiabetes hyperthyroidism insulin resistance insulin secretion reactive nitrogen species (RNS) reactive oxygen species (ROS)Type 2 diabetesCarbohydrate metabolismBiochemistryHyperthyroidism03 medical and health sciencesInsulin resistanceDiabetes mellitusInternal medicinemedicineHumansGlycemic030102 biochemistry & molecular biologyChemistryInsulinThyroidGeneral Medicinemedicine.diseaseReactive Nitrogen SpeciesOxygen030104 developmental biologymedicine.anatomical_structureEndocrinologyDiabetes Mellitus Type 2Insulin ResistanceReactive Oxygen SpeciesHormoneFree radical research
researchProduct

Prospective Trial of Functional Thyrotropin Receptor Antibodies in Graves Disease

2019

Abstract Context Scarce data exist regarding the relevance of stimulatory (TSAb) and blocking (TBAb) thyrotropin receptor antibodies in the management of Graves disease (GD). Objective To evaluate the clinical utility and predictive value of TSAb/TBAb. Design Prospective 2-year trial. Setting Academic tertiary referral center. Patients One hundred consecutive, untreated, hyperthyroid GD patients. Methods TSAb was reported as percentage of specimen-to-reference ratio (SRR) (cutoff SRR < 140%). Blocking activity was defined as percent inhibition of luciferase expression relative to induction with bovine thyrotropin (TSH, thyroid stimulating hormone) alone (cutoff > 40% inhibitio…

AdultMaleendocrine systemmedicine.medical_specialtyAdolescentendocrine system diseasesEndocrinology Diabetes and MetabolismGraves' diseaseClinical BiochemistryThyrotropinContext (language use)dilution analysisBiochemistryGastroenterologyThyrotropin receptorThyroid binding inhibitory immunoglobulinsYoung AdultMethimazoleEndocrinologyTSH-R stimulating antibodiesInternal medicineGraves hyperthyroidismmedicineHumansprospective trialProspective StudiesAutoantibodiesClinical Research Articlebiologybusiness.industryBiochemistry (medical)Receptors ThyrotropinMiddle AgedPrognosismedicine.diseaseeye diseasesGraves DiseaseTSH-R blocking antibodiesTiterEndocrinologyProspective trialbiology.proteinFemaleAntibodybusinessBiomarkersAcademicSubjects/MED00250Follow-Up Studiesmedicine.drugThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Subclinical hyperthyroidism due to a thyrotropin receptor (TSHR) gene mutation (S505R).

2006

Aim: To identify the molecular defect by which non-autoimmune subclinical hyperthyroidism was caused in a 6-mo-old infant who presented with weight loss. Methods: Congenital non-autoimmune hyperthyroidism is caused by activating germline mutations in the thyrotropin receptor (TSHR) gene. Therefore, the TSHR gene was sequenced directly from the patient's genomic DNA. Results: Molecular analysis revealed a heterozygous point mutation (S505R) in the TSHR gene as the underlying defect. Conclusion: A constitutively activating mutation in the TSHR gene has to be considered not only in patients with severe congenital non-autoimmune hyperthyroidism, but also in children with subclinical non-autoimm…

AdultMaleendocrine systemmedicine.medical_specialtyendocrine system diseasesAsymptomaticHyperthyroidismThyrotropin receptorTSHR Gene MutationGermline mutationInternal medicineMedicineMissense mutationHumansPoint MutationGeneSubclinical infectionbusiness.industryPoint mutationInfantReceptors ThyrotropinGeneral Medicineeye diseasesPedigreeEndocrinologyPediatrics Perinatology and Child HealthCancer researchFemalemedicine.symptombusinesshormones hormone substitutes and hormone antagonistsActa paediatrica (Oslo, Norway : 1992)
researchProduct

A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism—A Proof-of-Concept Trial

2019

Abstract Context The CD40-CD154 co-stimulatory pathway plays an important role in the pathogenesis of Graves disease (GD) by promoting autoreactive B-cell activation. Objective Evaluate efficacy and safety of a human, blocking, nondepleting anti-CD40 monoclonal antibody, iscalimab, in hyperthyroid patients with GD. Design Open-label, phase II proof-of-concept study. Setting Multicenter. Patients Fifteen with GD. Intervention Patients received 5 doses of iscalimab at 10 mg/kg intravenously over 12 weeks. Main outcome measures Thyroid-related hormones and autoantibodies, plasma soluble CD40, free CD40 on B cells, soluble CXCL13, pharmacokinetics, and safety were assessed. Results The iscalima…

AdultMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismGraves' diseasemedicine.medical_treatmentClinical BiochemistryContext (language use)Thyroid Function TestsHyperthyroidismProof of Concept StudyBiochemistryGastroenterologyThyrotropin receptorYoung AdultEndocrinologyThyroid peroxidaseInternal medicinemedicineHumansTissue DistributionCD40 AntigensAdverse effectAgedTriiodothyroninebiologybusiness.industryBiochemistry (medical)AutoantibodyAntibodies MonoclonalMiddle AgedPrognosismedicine.diseaseEndocrinologybiology.proteinFemaleThyroglobulinbusinessFollow-Up StudiesThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Nitric oxide mediates abnormal responsiveness of thyroid arteries in methimazole-treated patients.

2005

Objective: We studied the intervention of nitric oxide (NO), prostacyclin and endothelium-derived hyperpolarizing factor (EDHF) in mediating responses to acetylcholine in thyroid arteries from euthyroid and methimazole-treated (MT) patients. Design and methods: Branches of the superior thyroid artery were obtained from 19 euthyroid patients and 17 MT patients (euthyroid at the time of surgery) undergoing total thyroidectomy or hemithyroidectomy. Artery rings were suspended in organ baths for isometric recording of tension. Results and conclusions: Acetylcholine caused endothelium-dependent relaxation of greater magnitude in arteries from MT patients (pD2 (−log EC50) values were 7.68±0.19 in…

AdultMalemedicine.medical_specialtyPotassium ChannelsCharybdotoxinEndocrinology Diabetes and MetabolismMuscle RelaxationThyroid GlandApaminNitric OxideHyperthyroidismMuscle Smooth VascularSuperior thyroid arterychemistry.chemical_compoundBiological FactorsNorepinephrineEndocrinologyAntithyroid AgentsInternal medicinemedicine.arterymedicinePotassium Channel BlockersHumansEuthyroidEnzyme InhibitorsMethimazoleomega-N-Methylargininebusiness.industryThyroidGeneral MedicineArteriesMiddle AgedAcetylcholinemedicine.anatomical_structureEndocrinologychemistryApaminCirculatory systemPotassiumCalciumFemaleEndothelium VascularNitric Oxide SynthasebusinessAcetylcholinemedicine.drugBlood vesselArteryEuropean journal of endocrinology
researchProduct

Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in hyperthyroid patients.

2002

Cardiovascular manifestations are frequent findings in patients with thyroid hormone disorders. Nitric oxide (NO) plays a key role in vascular, endothelial-mediated relaxation. NO is synthesized from L-arginine by NO synthase, an enzyme inhibited by endogenous compounds, mainly asymmetric dimethylarginine [asymmetric N(G),N(G)-dimethyl-L-arginine (ADMA)]. The aim of our work was to investigate whether plasma L-arginine and dimethylarginine concentrations and NO production are altered in hypo- and hyperthyroid patients, compared with control subjects. L-arginine, ADMA and symmetric dimethylarginine were analyzed by HPLC. NO was measured as plasma nitrite plus nitrate (NO(x)) concentration by…

AdultMalemedicine.medical_specialtyendocrine system diseasesEndotheliumEndocrinology Diabetes and MetabolismClinical BiochemistryArginineNitric OxideBiochemistryHyperthyroidismNitric oxidechemistry.chemical_compoundEndocrinologyHypothyroidismGriess testReference ValuesInternal medicineBlood plasmamedicineHumansNitriteNitritesAgedNitratesbiologyBiochemistry (medical)Osmolar ConcentrationMiddle AgedNitric oxide synthaseEndocrinologymedicine.anatomical_structurechemistrybiology.proteinFemaleNitric Oxide SynthaseAsymmetric dimethylarginineHormoneThe Journal of clinical endocrinology and metabolism
researchProduct

Congenital hyperthyroidism with reciprocal translocation t(1;17)(q25;q21)

1989

The authors report a case of 1;17 translocation and request contact with colleagues who have observed similar cases.

Adultmedicine.medical_specialtyChromosomal translocationBiologyHyperthyroidismTranslocation GeneticCongenital hyperthyroidismEndocrinologyChromosomes Human Pair 1KaryotypingInternal medicineGeneticsmedicineHumansFemaleGenetics (clinical)Chromosomes Human Pair 17Human Genetics
researchProduct